Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 2,401–2,500 of 3,636
Clinical Management of Patients With Stable Ischemic Heart Disease
Dey, S., Wang, A. Y.-D., McMaster, M., Sanghavi, N., Frishman, W. H., & Aronow, W. S. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000557 · Cited by 2
Muscle-Related Adverse Events Associated With PCSK9 Inhibitors in a Veteran Population.
Cencetti, J., Abramowitz, C., & Spoonhower, H. (2023) · PubMed · doi:10.12877/fp.0357 · Cited by 2
Hypercholesterinämie und kardiovaskuläres Risiko
Sinning, D., & Landmesser, U. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1932-6448 · Cited by 2
Development of a standard set of data variables and a database platform for panvascular disease
Yang, J., Su, X., Dong, Z., Yang, P., Shi, X., Wang, J., Zheng, X., Tong, Z., Zhang, H., Hu, H., et al. (2023) · Cardiology Plus · doi:10.1097/cp9.0000000000000066 · Cited by 2
Genetically proxied PCSK9 inhibition is associated with reduced psoriatic arthritis risk
Li, J., Li, J., Lin, C., Zhou, J., Wang, J., Wang, F., Li, H., & Zhou, Z. (2024) · Inflammation Research · doi:10.1007/s00011-024-01850-3 · Cited by 3
“Its significance as a pivotal therapeutic target for hypercholesterolemia and coronary heart disease attenuation is evident [26].”
BackgroundUpdates on Non-Statin LDL-Lowering Therapy
Abdulla, A., Shalaby, M., Kumfa, P. N., Raja, M. W., Allencherril, J., & Sharifeh, T. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02028-3 · Cited by 5
“They reduce LDL levels by about 50–60% [15, 16].”
Brennan, P. G., Mota, L., Aridi, T. G., Patel, N., Liang, P., & Ferran, C. J. (2024) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2024.01.031 · Cited by 2
Bang, L. E., Jensen, J. K., Räber, L., et al. (2024) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2024.04.001 · Cited by 2
Pharmacological methods to lower lipoprotein(a) levels
Wierzbowska, N., Olejnik-Wojciechowska, J., Dąbrowska, A., & Żurawska, K. (2024) · Medical Research Journal · doi:10.5603/mrj.99088 · Cited by 2
Wang, H., Mao, Y.-C., Qi, S.-F., Xu, X., Zhang, Z., Geng, C., Song, K., & Tian, Q. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00651-7 · Cited by 3
Natale, F., Franzese, R., Marotta, L., Mollo, N., Solimene, A., Luisi, E., Gentile, C., Loffredo, F. S., Golino, P., & Cimmino, G. (2024) · Life · doi:10.3390/life14060679 · Cited by 4
“In particular, the use of PCSK9 inhibitors in combination with high-intensity statins has led to an unprecedented reduction in LDL-C, with median LDL levels of 30 mg/dL in the FOURIER study [75,76] and 40 mg/dL within 4 months in the ODYSSEY-OUTCOMES trial [77].”
BackgroundMárk, L., Fülöp, P., Lőrincz, H., Dani, G., Tajtiné, K. F., Thury, A. Á., & Paragh, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123398 · Cited by 2
“Results from previous studies have shown that reducing serum low-density lipoprotein cholesterol (LDL-C) levels inhibits the progression of atherosclerosis [1–5].”
BackgroundManagement of vulnerable patient phenotypes and acute coronary syndrome mechanisms
Vito, L. D., Giusto, F. D., Mazzotta, S., Scalone, G., Bruscoli, F., Silenzi, S., Selimi, A., Angelini, M., Galieni, P., & Grossi, P. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132365 · Cited by 5
Ramírez-Peña, T., Corredor-Orlandelli, D., Fernández-Ávila, D. G., Peña, Á. A. G., & Múñoz, Ó. (2024) · REC CardioClinics · doi:10.1016/j.rccl.2024.06.003 · Cited by 3
Mohyeldin, M., Abuelgasim, A. S., & Mustafa, A. (2024) · World Journal of Cardiology · doi:10.4330/wjc.v16.i7.397 · Cited by 2
Zeliaś, A., Bednarek, A., Dykla, D., Korpak-Wysocka, R., Szczygiel, P., & Dudek, D. (2024) · Kardiologia Polska · doi:10.33963/v.phj.101554 · Cited by 3
Reuser, A., Look, C., & Laufs, U. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2332-9120 · Cited by 2
van Bruggen, F. H., de Haas, E. C., Zuidema, S. U., & Luijendijk, H. J. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00668-y · Cited by 2
Elnaggar, M., Miller, A. M., Sil, A., & Viljoen, A. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2400273 · Cited by 2
“…is preferred due to the availability of published large scale CV outcomes trial data showing reductions in CV events/mortality as well as long term safety 18,25–28 , while inclisiran is selected for patients within the range of 2.6–3.5 mmol/L only, as CV outcomes trials are still ongoing 29,30 .”
InfluentialNovel approaches to lipid lowering
Averna, M. R. (2024) · European Atherosclerosis Journal · doi:10.56095/eaj.v3i2.75 · Cited by 2
“The two outcomes trials, FOURIER and ODYSSEY Outcomes, have demonstrated significant reductions in cardiovascular events and mortality [6, 7].”
Stach, K., Richter, H., Fraass, U., & Stein, A. (2024) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447241277402 · Cited by 2
Prognosis of patients with coronary artery disease and diabetes — what to look for
Nekrasov, A. A., Тимощенко, Е. С., Анатольевна, Н. Т., & Bakhrak, E. V. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6030 · Cited by 2
Bruun, K., & Mortensen, M. B. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001188 · Cited by 2
Sex differences in LDL ‐C reduction response to evolocumab: A propensity score matching analysis
He, Y., Wei, Y., Guang-ming, H., Liu, G., Lin, Z., Liu, T., Jiang, X., & Lu, J. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4619 · Cited by 2
Can apoA-I infusion decrease cardiovascular events?
Tokgözoğlu, L. S., Pirillo, A., & Catapano, A. L. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae774 · Cited by 2
Naami, R., Miller, D. M., Datla, S., Rahman, M. U., Al-Kindi, S. G., & Neeland, I. J. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000746 · Cited by 5
Park, G., Choi, E., & Lee, S. (2024) · Korean Circulation Journal · doi:10.4070/kcj.2024.0218 · Cited by 2
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia
Ahmad, M., & Hegele, R. A. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00768-0 · Cited by 5
“[28].”
InfluentialAdministration of Evolocumab in Patients with STEMI After Emergency PCI: A Real-World Cohort Study
Sun, X., Bai, S., Wu, H., Wang, T., & Du, R. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00722-3 · Cited by 2
“Similar outcomes were reported in the ODYSSEY OUTCOMES trial, another large-scale randomized controlled trial, where alirocumab reduced 190 initial and 385 total non-fatal cardiovascular events or deaths compared with placebo [23].”
Muiesan, M., Virdis, A., Tocci, G., Borghi, C., Cicero, A., Ferri, C., Pirro, M., Corsini, A., & Volpe, M. (2025) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00700-x · Cited by 2
“Relative to alirocumab, the ODYSSEY OUTCOMES trial [40] showed a reducing in major CV events by 15% when compared to placebo in patients with recent acute coronary syndrome.”
Avogaro, A., Buzzetti, R., Candido, R., Cosmo, S. D., Notarianni, L., Consolo, E., & Luciano, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112055 · Cited by 3
Wan, Y., Liu, J., Zhan, X., Zhang, Y., & You, R. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00733-0 · Cited by 3
“%) and alirocumab (54.7%), while offering a more convenient dosing schedule (Q4W versus every 2 weeks (Q2W)) [15, 16].”
InfluentialXu, H., Wang, Z., Chen, D., Zhang, H., Ge, J., & Li, J. (2025) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.31543 · Cited by 3
“C levels an improving cardiovascular outcomes [37 – 39].”
Efficacy and safety of PCSK9 inhibitors in real life
González-Guerrero, A., Navarrete-Rouco, E., Benaiges, D., Steinhauer, E. G., Marcos, L., Oliveras, A., Recasens, L., & Pedro‐Botet, J. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.500755 · Cited by 2
Lp(a): Global Public Health Concern: Emerging Knowledge and Therapeutic Approaches
Razavi, A. C., Hong, J., & Bhatia, H. S. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02255-2 · Cited by 3
“The ODYSSEY [61] and FOU-RIER [62] trials demonstrated that the addition of PCSK9 progression of aortic stenosis and a novel therapeutic target [53].”
Ogunniyi, K. E., Aghasili, C. C., Akinmoju, O. D., Olaiya, V. O., Abib, O. M., Odueke, A., Popoola, H. A., Onyenokwe, V., Onaolapo, D., Usman, A.-A. M., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00762-9 · Cited by 3
“This makes them particularly well-suited for patients with polypharmacy or those at risk of CYP3A4-mediated interactions [27, 28, 30, 67].”
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
Zhang, D., Wu, H., & Gong, S. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2510693 · Cited by 2
Matsumoto, I., Mukaida, K., Wada, K., Kurozumi, M., Namba, T., & Takagi, Y. (2025) · Circulation Reports · doi:10.1253/circrep.cr-25-0091 · Cited by 6
Yu, C., Wang, T., Zhu, L., Zhou, W., Bao, H., & Cheng, X. (2025) · BMC Public Health · doi:10.1186/s12889-025-24635-7 · Cited by 3
“While statins remain first-line therapy for ASCVD [12], residual cardiovascular risk persists despite low-density lipoprotein cholesterol (LDL-C) reduction [12], prompting focus on triglyceride-rich lipoproteins (TRLs) and remnant cholesterol (RC) [13].”
Sex differences in coronary artery disease
Seegers, L. M. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04751-2 · Cited by 5
Lipoprotein(a) and Vascular Redox State in Patients With Advanced Coronary Atherosclerosis
Polkinghorne, M., Badi, I., Baragetti, A., Chauhan, J. S., Xie, C., Wahome, E., Akoumianakis, I., Foran, D., Patel, P., de Araujo, E., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.322924 · Cited by 6
Satyanarayanan, Y. V., Rayaprolu, V. L. G., Durugu, S. R., Katukuri, N., & Nemani, L. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_59_2025 · Cited by 2
Alothman, L., Zawadka, M., Aljenedil, S., Kajil, M., Bewick, D. J., Gaudet, D., Hegele, R. A., Lonn, E., Ngui, D., Ruel, I. L., et al. (2019) · CJC Open · doi:10.1016/j.cjco.2019.05.006 · Cited by 4
Merrelaar, A. E., Buchtele, N., Schriefl, C., Clodi, C., Poppe, M., Ettl, F., Herkner, H., Jilma, B., Schwameis, M., & Schoergenhofer, C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082606 · Cited by 2
“Until now, two anti-PCSK–9 antibodies have been marketed: in the pivotal trials, alirocumab and evolocumab both demonstrated potent lipid-lowering effects and both reduced the risk to develop cardiovascular events in risk populations [5,6].”
BackgroundResampling‐based stepwise multiple testing procedures with applications to clinical trial data
He, J., Li, F., Gao, Y., & Rothmann, M. D. (2020) · Pharmaceutical Statistics · doi:10.1002/pst.2076 · Cited by 3
Skoczyńska, A., Wawrzynowicz‐Syczewska, M., Barlik-Rysa, M., Danik, A., Różański, J., Filipiak, K. J., & Cybulska, B. (2020) · Folia Cardiologica · doi:10.5603/fc.2020.0001 · Cited by 1
Managed care pharmacist updates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
Patel, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88608 · Cited by 3
Lucki, M., Chlebuś, E., Wareńczak, A., & Lisiński, P. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18116021 · Cited by 2
When is it Appropriate to Lower Low Density Lipoprotein-Cholesterol Levels to <30 mg/dL?
Wong, N. D., Puri, R., Mehta, V., & Duell, P. B. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.06.041 · Cited by 2
Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis
Masson, W. M., Lobo, M., Cobo, A. L., & Molinero, G. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.06.001 · Cited by 5
Андреевна, Г. О., Galati, G., VACHEV, A., Germanov, A. V., & Biondi‐Zoccai, G. (2022) · Panminerva Medica · doi:10.23736/s0031-0808.21.04608-5 · Cited by 3
Noel, A., & Genest, J. J. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.11.022 · Cited by 2
The 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?
Thanassoulis, G., Grégoire, J. C., & Pearson, G. J. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.03.003 · Cited by 2
Efficacité et sécurité des inhibiteurs de PCSK9 dans le diabète
Dijk, W., May, C. L., & Cariou, B. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30044-6 · Cited by 2
Chuzi, S. E., Pfenniger, A., Lloyd‐Jones, D. M., Blumenthal, R. S., Smith, S. C., Virani, S. S., Grundy, S. M., & Stone, N. J. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0771 · Cited by 2
Diabetic outcomes: Cardiovascular outcomes with lipid modification H2D
Lepor, N. E. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12931 · Cited by 2
“evaluating alirocumab and FOURIER evaluating evolocumab, confirmed benefit in diabetic patients.(9,10) With evolocumab there was a significant 17% reduction in the primary composite endpoint of CV death, MI, stroke, unstable angina or revascularization.”
BackgroundA case of repetitive acute coronary syndrome in a patient with familial hypercholesterolemia
Motozato, K., Sueta, D., Sakamoto, K., Nagamatsu, S., Yamashita, T., Sato, R., Mitsuse, T., Kanemaru, Y., Takaoka, K., Fujisue, K., et al. (2019) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2019.08.007 · Cited by 2
Acute Coronary Syndromes and the Nontarget Lesion
Schüpke, S., & Tiroch, K. A. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.027 · Cited by 3
2019 clinical trials in lipid lowering
Feldman, D. I., Pacor, J., Blumenthal, R. S., & Nasir, K. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000757 · Cited by 2
Adverse events to PCSK-9 inhibitors: what is the current evidence?
Floyd, C., & Crook, M. A. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138746 · Cited by 2
Lin, S., He, X., Zhai, G., Wang, C., Xue, H., & Lin, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13283 · Cited by 3
Effects and Issues of Diet Fat on Cardiovascular Metabolism
Nishikawa, Y. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.93261 · Cited by 3
“In the two PCSK9 inhibitors, evolocumab [181] and alirocumab [182], NNT value was 67 persons/2.”
BackgroundShould We Target Global Risk or Risk Factors?
Tokgözoğlu, L. S., & Koçyiğit, D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00898-w · Cited by 2
Alkhalil, M. (2021) · Current Cardiology Reviews · doi:10.2174/1573403x17666210202102549 · Cited by 2
“sulted in a reduction of adverse cardiovascular events in patients with previous MI [63, 70].”
BackgroundTakahashi, N., Dohi, T., Endo, H., & Okazaki, S. (2021) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytab095 · Cited by 3
Ha, J., Lee, B., Park, J. M., Kang, M., Oh, J., Lee, C. J., Park, S., Kang, S., & Lee, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-88416-z · Cited by 2
Sekundärprävention nach TIA oder ischämischem Schlaganfall
Diener, H., & Nickenig, G. (2021) · Herz · doi:10.1007/s00059-021-05035-0 · Cited by 2
Pharmacological Management of Hyperlipidemia in Older Individuals
Tsu, L. V., Carroll, K. A., Kindler, K., & Early, N. K. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2021.284 · Cited by 2
Nuevos tratamientos en la dislipemia
de Isla, L. P., & Valdivielso, P. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.003 · Cited by 5
Stock, J. K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.013 · Cited by 3
Skutki hamowania funkcji PCSK9 w obrębie wybranych tkanek *
Maligłówka, M., Bułdak, Ł., Okopień, B., & Bołdys, A. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0014.9127 · Cited by 2
Diabetes mellitus and acute coronary syndromes
Serhiyenko, V. A., & Serhiyenko, A. A. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.4.2021.237351 · Cited by 2
Persistent inflammatory residual risk despite aggressive cholesterol-lowering therapy: what is next?
Arnold, N., & Köenig, W. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000909 · Cited by 2
Evaluation of the Effectiveness and Safety of Alirocumab Use in Statin-Intolerant Veterans
Imarhia, F. I., Sulaica, E. M., Varisco, T. J., & Pilate, M. (2021) · Federal Practitioner · doi:10.12788/fp.0176 · Cited by 3
van der Laarse, A., & Cobbaert, C. M. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.2022475 · Cited by 4
The Role of Statins in Prevention of Cardiovascular Diseases in Real Clinical Practice
IuA, K., & Moscow, R. F. (2021) · Doctor Ru · doi:10.31550/1727-2378-2021-20-11-17-27 · Cited by 4
ATHEROSCLEROSIS and LDL-cholesterol : Another Brick In The Wall
Pasteur‐Rousseau, A., & Tedgui, A. (2022) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2021.10.020 · Cited by 2
Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease
Noh, S., Mai, K., Shaver, M., Yong, S., MOSTAGHIMI, M., Oh, G., & Radwan, M. M. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.12.011 · Cited by 3
Safety Issues Associated With the Clinical Application of PCSK9 Inhibitors: Current Findings
Wang, D., & Zhang, D. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000441 · Cited by 2
“Clinical trials of PCSK9 inhibitors have shown excellent safety consistently, with no significantly increased risk of hepatic impairment.(2,4,7) An open-label, parallel-group study evaluated the pharmacokinetics of evolocumab in hepatic-impaired (Child-Pugh Class A or B) and healthy adults.”
BackgroundAriss, R. W., & Gupta, R. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221084772 · Cited by 2
“In a sensitivity analysis, the results from the IMPROVE-IT trial results were replaced with those from the ODYSSEY OUTCOMES which studied the addition of alirocumab to statin for the secondary prevention of cardiovascular events.(12) The IMPROVE-IT trial was replaced as the effect sizes of ezetimibe on the endpoints w…”
MethodTopical issues concerning modern lipid-lowering therapy
Susekov, A. V. (2022) · Consilium Medicum · doi:10.26442/20751753.2022.1.201484 · Cited by 2
The PACMAN-AMI trial: game over for the “vulnerable plaque”?
Vergallo, R., & Patrono, C. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac222 · Cited by 2
Clinical strategies for reducing cholesterol levels
Lardinois, C. K., & Karr, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00027-4 · Cited by 2
Backer, G. D. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac111 · Cited by 2
Zeng, Y. H., & Zhao, D. (2022) · Cardiology Discovery · doi:10.1097/cd9.0000000000000053 · Cited by 2
“0 mmol/L does not increase the risk of severe adverse events.([7,31,32]) Using statins to lower LDL-C is an important cornerstone in the prevention and treatment of ASCVD.”
BackgroundPedro‐Botet, J., Barrios, V., Sánchez‐Margalet, V., Tamargo, J. L., Arrieta, F., Gámez, J. M., Gimeno-Orna, J. A., Escobar, C., Gómez‐Doblas, J. J., & Pérez, A. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.03.004 · Cited by 5
Bobrowska, B., Krawczyk‐Ożóg, A., Bartuś, S., & Rajtar-Salwa, R. (2022) · Advances in Interventional Cardiology · doi:10.5114/aic.2022.118533 · Cited by 2
“9% of patients and there was no significant difference from placebo groups [15].”
BackgroundShawky, A., Bendary, A., Elbahry, A., Farag, E.-S. M., Mostafa, T. M. N., Sanad, O., Elkersh, A., Selim, M., Ragy, H. I., Khamis, H., et al. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00277-3 · Cited by 2
“8 years; relative risk reduction, 14%) [20].”
BackgroundPeripheral Artery Disease (PAD)
Cluckey, A., Dahm, C. N., & Chacko, M. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-16594-8_5 · Cited by 2
Bempedoic acid: a CLEAR therapeutic option for statin-intolerant patients?
Volpe, M., & Patrono, C. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad206 · Cited by 2
The Role of RNA Interference Therapeutics in Hypercholesterolemia and Implications for Practice
DePhillips, C. (2023) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2023.104619 · Cited by 2
The Ability to Look Beyond: The Treatment of Peripheral Arterial Disease
Sirignano, P., Margheritini, C., Ruggiero, F., Panzano, C., Filippi, F., Rizzo, L., & Taurino, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093073 · Cited by 4
“Recent studies have shown that lowering LDL-C is linked to MACE and MALE occurrence reduction, especially for high-risk patients [27,28].”
BackgroundFISIOPATOLOGIA E TRATAMENTOS ATUALMENTE DISPONÍVEIS PARA DISLIPIDEMIA
Almeida, A. B., Pontes, B. B., Gioia, L. N., & Rangel, V. (2023) · EPITAYA eBooks · doi:10.47879/ed.ep.2023809p32 · Cited by 5
Cai, H., Zheng, R., Wu, N., Hu, J., Wang, R., Chi, J., Zhang, W., Zhao, L., Cheng, H. B., Chen, A., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102377 · Cited by 2
Eligibility for Icosapent Ethyl in a French Population of Coronary Outpatients With Type 2 Diabetes
Sabouret, P. F., Dib, J.-C., Ecarnot, F., et al. (2023) · Archives of Medical Science · doi:10.5114/aoms/173511 · Cited by 2
“An underestimation of benefits provided by a profound decrease in LDL-C, and suboptimal knowledge of randomized cardiovascular outcomes trials testing ezetimibe (IMPROVE-IT)[8] or PCSK9i (FOURIER and ODYSSEY Outcomes)[9, 10] by cardiologists or general practitioners who P r p r n are not experts in this field, also se…”
BackgroundWang, X., Wen, D., Fang, M., You, C., & Ma, L. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2410286 · Cited by 2
Vila, À., Pons, E., García, P. T., Vidal, D., López, S., & Grau, A. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.06.003 · Cited by 2
Likozar, A. R., Ugovšek, S., & Šebeštjen, M. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176232 · Cited by 4
Lp(a) and risk of cardiovascular disease – A review of existing evidence and emerging concepts
Jasti, M., Islam, S., Steele, N., Ivy, K. N., Maimo, W., & Isiadinso, I. (2023) · Journal of the National Medical Association · doi:10.1016/j.jnma.2023.11.009 · Cited by 3
Nguyễn, H. Đ., Hoàng, A. T., Bùi, D. H., Nguyễn, N. K. Q., Phan, C. S., & Trương, V. K. N. (2023) · Tạp chí Tim Mạch Học Việt Nam · doi:10.58354/jvc.106.2023.480 · Cited by 2
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

